Form 4: Zentalis Officer Sells Shares for Tax, 10b5-1 Plan

Zentalis Pharmaceuticals officer Vincent Vultaggio sold common stock shares in early February 2026, partly to cover tax obligations and partly under a pre-arranged trading plan.

Summary

• Vincent Vultaggio, an officer (PAO and PFO) of Zentalis Pharmaceuticals, Inc. (ZNTL), reported two sales of common stock.
• On February 2, 2026, Vultaggio sold 2,540 shares of common stock at a price of $2.55 per share. This sale was automatically executed by the Issuer to cover tax withholding obligations related to the vesting and settlement of previously granted restricted stock units.
• Following this transaction, Vultaggio beneficially owned 187,286 shares of common stock.
• On February 3, 2026, Vultaggio sold an additional 556 shares of common stock at a price of $2.515 per share. This sale was conducted pursuant to a Rule 10b5-1 trading arrangement adopted by the reporting person.
• After the second transaction, Vultaggio's direct beneficial ownership of common stock stood at 186,730 shares.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive disclosure. While insider sales can sometimes be perceived negatively, the stated reasons (tax withholding and a pre-arranged 10b5-1 plan) suggest these were not discretionary sales based on a negative view of the company, mitigating potential concerns.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, particularly those for tax withholding or executed under a pre-arranged 10b5-1 plan, are common and typically do not signal a change in management's outlook on the company's future performance. These types of transactions are often part of routine personal financial management for executives.

Stakeholder Impact

• Shareholders: May observe these sales as routine insider activity, especially given the stated reasons, and are unlikely to interpret them as a significant signal regarding the company's operational health or future prospects.

Key Dates

Recommendation

A 'hold' recommendation is appropriate as this Form 4 filing primarily details routine insider stock transactions for tax purposes and a pre-scheduled trading plan. It does not provide new information regarding Zentalis Pharmaceuticals' operational performance, strategic direction, or financial health that would warrant a change in investment thesis. Investors should look to broader company reports and market conditions for investment decisions.

Keywords

Zentalis Pharmaceuticals, ZNTL, Form 4, Insider Trading, Stock Sale, Vincent Vultaggio, 10b5-1 Plan, Tax Withholding